Media Coverage

New research by Quest Diagnostics suggests that more and more U.S. workers are using the powerful synthetic opioid drug fentanyl, since it’s showing up in random drug tests carried out in workplaces across the country. This bleak news might not be too surprising, given the dramatic speed with which the drug has affected a population that remains plagued by opioid addiction.

Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications. This service is intended to support clinicians in selecting appropriate drugs and determining optimal dosages.

More Americans are testing positive for fentanyl use in randomized workplace drug tests, highlighting a persistent challenge for employers. The positive rate for urine tests indicating the presence of the synthetic opioid fentanyl was 1.13% in 2024. That is up from 0.91% in 2023 and double the rate in 2020, according to a recent analysis of more than eight million drug tests by Quest Diagnostics, one of the U.S.’s largest drug-testing labs.

Jeff Lusby is the general manager of healthcare IT solutions at Quest Diagnostics. With more than 29 years in healthcare IT, Lusby has extensive experience with technology implementations, from the sales journey to installation, support and account management. In his current role, he leads Quest’s Quanum Enterprise Content Solutions software business.

Corewell Health has signed on to a joint venture with Quest Diagnostics covering inpatient and outpatient lab management and the construction of a new 100,000-square-foot advanced lab facility.